☆ 4.6 Article

Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Related references

Note: Only part of the references are listed.

Letter Hematology

Caplacizumab: frequent local skin reactions

Jessica Kaufeld et al.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker et al.

Summary: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal disease caused by severe deficiency of ADAMTS13, and standardized definitions of response and exacerbation primarily based on platelet count have been modified to incorporate ADAMTS13 activity and the effects of anti-VWF therapy. The revised definitions distinguish between clinical and ADAMTS13 remission and relapse, and are benchmarked against not only the timing of discontinuation of therapeutic plasma exchange (TPE) but also that of anti-VWF therapy. Validation of the revised definitions is retrospective, with discussion on the clinical implications of the updated outcome definitions.

BLOOD (2021)

Add to Collection

Article Hematology

Real-world experience with caplacizumab in the management of acute TTP

Tina Dutt et al.

Summary: In a real-world study of 85 patients receiving caplacizumab, it was found that caplacizumab in combination with PEX and other treatments effectively shortened the time to platelet count normalization in a clinical setting, demonstrating favorable outcomes compared to historical controls.

BLOOD (2021)

Add to Collection

Letter Hematology

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab

Senthil Sukumar et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Hematology

Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma

Mehraboon S. Irani et al.

TRANSFUSION (2020)

Add to Collection

Article Hematology

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

Linus A. Voelker et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Linus A. Voelker et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab

Linus A. Voelker et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Paul Coppo et al.

BLOOD (2020)

Add to Collection

Review Pharmacology & Pharmacy

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Maria Laura Sargentini-Maier et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)

Add to Collection

Letter Medicine, General & Internal

Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura

Deepak P. Chander et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

M. Scully et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies

M. Scully et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)

Add to Collection

Review Hematology

Pathophysiology of thrombotic thrombocytopenic purpura

J. Evan Sadler

BLOOD (2017)

Add to Collection

Letter Hematology

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura

Evaren E. Page et al.

BLOOD (2016)

Add to Collection

Article Medicine, General & Internal

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Hematology

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts et al.

BLOOD (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.